Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders.
Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Elsevier Science Publishing Co Inc
Zielgruppe
Für höhere Schule und Studium
Clinicians, drug developers in industry and academia, and graduate students in behavioral neuroscience, neurobiology, translational neuroscience, clinical psychiatry, and pharmaceutical science
Produkt-Hinweis
Fadenheftung
Gewebe-Einband
Maße
Höhe: 282 mm
Breite: 218 mm
Dicke: 25 mm
Gewicht
ISBN-13
978-0-12-803161-2 (9780128031612)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Klassifikation
Dr. Nomikos has more than 30 years of experience in neuropsychopharmacology and CNS therapeutics in both academia and the pharmaceutical/biotechnology industry, focusing on CNS translational and experimental medicine and clinical drug development in psychiatry and neurology. Dr. Feltner has more than 20 years of experience in drug development and translational medicine. He has held previous positions leading neuroscience development at Abbvie and leading Translational Medicine at Pfizer.
Herausgeber*in
Global Medical Lead, Clinical Development, Biogen, Cambridge, MA, USA
Vice President, Head of Clinical Development, at AveXis, a Novartis company.
1. Translating animal models of obesity and diabetes to the clinic
2. Biomarker-guided drug development for better defined early patient studies and clinical trial efficiency
3. Modeling and simulation in the translational pharmacology of cns drugs
4. Functional measurements of central nervous system drug effects in early human drug development
5. Experimental medicine approaches in cns drug development
6. New approaches in translational medicine for phase i clinical trials of cns drugs
7. Translational approaches for antidepressant drug development
8. Biomarker opportunities to enrich clinical trial populations for drug development in schizophrenia and depression
9. Applications of neuroimaging biomarkers in cns drug development
10. Pet occupancy and competition in translational medicine and cns drug development
11. Stable isotope labeling kinetics in cns translational medicine: introduction to silk technology
12. Applications of neurophysiological biomarkers in cns drug development: focus on psychoses
13. Heart rate variability as a translational biomarker for emotional and cognitive deficits
14. Drug discovery in psychiatry: time for human genome-guided solutions
15. Use of cognition to guide decisions about the safety and efficacy of drugs in early-phase clinical trials
16. Digital biomarkers in clinical drug development
17. Lessons learned from public private partnerships and consortia: the adni paradigm
18. Regulatory perspectives on the use of biomarkers and personalized medicine in cns drug development: the fda viewpoint
19. Regulatory considerations for the use of biomarkers and personalized medicine in cns drug development: a european perspective
20. Regulatory science objectives and biomarker qualification through public-private partnerships are critical to delivering innovative treatments for cns diseases
21. The assessment of cognition in translational medicine: a contrast between the approaches used in alzheimer's disease and major depressive disorder
22. Translational medicine strategies in drug development for neurodevelopmental disorders
23. Translational medicine strategies in drug development for mood disorders
24. Translational medicine strategies in alzheimer's disease drug development
25. Experimental medicine models in generalized anxiety disorder and social anxiety disorder
26. Translational medicine strategies in ptsd drug development
27. Unmet medical needs in the treatment of depression and the clinical development of a differentiated antidepressant: a translational line of evidence
28. Translating neurobiology into practice in tobacco, alcohol, drug, and behavioral addictions
29. Translational medicine strategies for drug development for impulsive aggression
30. Hypothesizing major depression as a subset of reward deficiency syndrome (rds) linked to polymorphic reward genes: considerations for translational medicine approaches for future drug development
31. Traveling through the storm: leveraging virtual patient monitoring and artificial intelligence to observe, predict, and affect patient behavior in cns drug development
